338 related articles for article (PubMed ID: 23460513)
1. Nanogel-based PspA intranasal vaccine prevents invasive disease and nasal colonization by Streptococcus pneumoniae.
Kong IG; Sato A; Yuki Y; Nochi T; Takahashi H; Sawada S; Mejima M; Kurokawa S; Okada K; Sato S; Briles DE; Kunisawa J; Inoue Y; Yamamoto M; Akiyoshi K; Kiyono H
Infect Immun; 2013 May; 81(5):1625-34. PubMed ID: 23460513
[TBL] [Abstract][Full Text] [Related]
2. Nasal vaccination with pneumococcal surface protein A in combination with cationic liposomes consisting of DOTAP and DC-chol confers antigen-mediated protective immunity against Streptococcus pneumoniae infections in mice.
Tada R; Suzuki H; Takahashi S; Negishi Y; Kiyono H; Kunisawa J; Aramaki Y
Int Immunopharmacol; 2018 Aug; 61():385-393. PubMed ID: 29945026
[TBL] [Abstract][Full Text] [Related]
3. Characterization and Specification of a Trivalent Protein-Based Pneumococcal Vaccine Formulation Using an Adjuvant-Free Nanogel Nasal Delivery System.
Yuki Y; Uchida Y; Sawada SI; Nakahashi-Ouchida R; Sugiura K; Mori H; Yamanoue T; Machita T; Honma A; Kurokawa S; Mukerji R; Briles DE; Akiyoshi K; Kiyono H
Mol Pharm; 2021 Apr; 18(4):1582-1592. PubMed ID: 33621107
[TBL] [Abstract][Full Text] [Related]
4. Nanogel-based pneumococcal surface protein A nasal vaccine induces microRNA-associated Th17 cell responses with neutralizing antibodies against Streptococcus pneumoniae in macaques.
Fukuyama Y; Yuki Y; Katakai Y; Harada N; Takahashi H; Takeda S; Mejima M; Joo S; Kurokawa S; Sawada S; Shibata H; Park EJ; Fujihashi K; Briles DE; Yasutomi Y; Tsukada H; Akiyoshi K; Kiyono H
Mucosal Immunol; 2015 Sep; 8(5):1144-53. PubMed ID: 25669148
[TBL] [Abstract][Full Text] [Related]
5. Protection elicited by nasal immunization with pneumococcal surface protein A (PspA) adjuvanted with bacterium-like particles against Streptococcus pneumoniae infection in mice.
Li B; Chen X; Yu J; Zhang Y; Mo Z; Gu T; Kong W; Wu Y
Microb Pathog; 2018 Oct; 123():115-119. PubMed ID: 29959043
[TBL] [Abstract][Full Text] [Related]
6. Intranasal immunization with recombinant PspA fused with a flagellin enhances cross-protective immunity against Streptococcus pneumoniae infection in mice.
Nguyen CT; Kim SY; Kim MS; Lee SE; Rhee JH
Vaccine; 2011 Aug; 29(34):5731-9. PubMed ID: 21696869
[TBL] [Abstract][Full Text] [Related]
7. Broad protective immune responses elicited by bacterium-like particle-based intranasal pneumococcal particle vaccine displaying PspA2 and PspA4 fragments.
Lu J; Guo J; Wang D; Yu J; Gu T; Jiang C; Kong W; Wu Y
Hum Vaccin Immunother; 2019; 15(2):371-380. PubMed ID: 30235046
[TBL] [Abstract][Full Text] [Related]
8. A nanogel-based trivalent PspA nasal vaccine protects macaques from intratracheal challenge with pneumococci.
Nakahashi-Ouchida R; Uchida Y; Yuki Y; Katakai Y; Yamanoue T; Ogawa H; Munesue Y; Nakano N; Hanari K; Miyazaki T; Saito Y; Umemoto S; Sawada SI; Mukerji R; Briles DE; Yasutomi Y; Akiyoshi K; Kiyono H
Vaccine; 2021 Jun; 39(25):3353-3364. PubMed ID: 34016473
[TBL] [Abstract][Full Text] [Related]
9. Role of antibodies and IL17-mediated immunity in protection against pneumococcal otitis media.
Habets MN; van Selm S; van Opzeeland FJ; Simonetti E; Hermans PWM; de Jonge MI; Diavatopoulos DA
Vaccine; 2016 Nov; 34(48):5968-5974. PubMed ID: 27771185
[TBL] [Abstract][Full Text] [Related]
10. Oral immunization with PspA elicits protective humoral immunity against Streptococcus pneumoniae infection.
Yamamoto M; McDaniel LS; Kawabata K; Briles DE; Jackson RJ; McGhee JR; Kiyono H
Infect Immun; 1997 Feb; 65(2):640-4. PubMed ID: 9009325
[TBL] [Abstract][Full Text] [Related]
11. PspA family fusion proteins delivered by attenuated Salmonella enterica serovar Typhimurium extend and enhance protection against Streptococcus pneumoniae.
Xin W; Li Y; Mo H; Roland KL; Curtiss R
Infect Immun; 2009 Oct; 77(10):4518-28. PubMed ID: 19687204
[TBL] [Abstract][Full Text] [Related]
12. Mucosal immunization with an unadjuvanted vaccine that targets Streptococcus pneumoniae PspA to human Fcγ receptor type I protects against pneumococcal infection through complement- and lactoferrin-mediated bactericidal activity.
Bitsaktsis C; Iglesias BV; Li Y; Colino J; Snapper CM; Hollingshead SK; Pham G; Gosselin DR; Gosselin EJ
Infect Immun; 2012 Mar; 80(3):1166-80. PubMed ID: 22158740
[TBL] [Abstract][Full Text] [Related]
13. Combined prime-boost immunization with systemic and mucosal pneumococcal vaccines based on Pneumococcal surface protein A to enhance protection against lethal pneumococcal infections.
Zhang Y; Guo X; Guo M; Chen X; Li B; Yu J; Gu T; Kong W; Wu Y
Immunol Res; 2019 Oct; 67(4-5):398-407. PubMed ID: 31773490
[TBL] [Abstract][Full Text] [Related]
14. Protective Immune Responses Elicited by Fusion Protein Containing PsaA and PspA Fragments.
Lu J; Sun T; Wang D; Dong Y; Xu M; Hou H; Kong FT; Liang C; Gu T; Chen P; Sun S; Lv X; Jiang C; Kong W; Wu Y
Immunol Invest; 2015; 44(5):482-96. PubMed ID: 26107747
[TBL] [Abstract][Full Text] [Related]
15. Protection against systemic fatal pneumococcal infection by maternal intranasal immunization with pneumococcal surface protein A (PspA).
Katsurahara T; Hotomi M; Yamauchi K; Billal DS; Yamanaka N
J Infect Chemother; 2008 Dec; 14(6):393-8. PubMed ID: 19089550
[TBL] [Abstract][Full Text] [Related]
16. Intranasal vaccination against angiotensin II type 1 receptor and pneumococcal surface protein A attenuates hypertension and pneumococcal infection in rodents.
Azegami T; Yuki Y; Hayashi K; Hishikawa A; Sawada SI; Ishige K; Akiyoshi K; Kiyono H; Itoh H
J Hypertens; 2018 Feb; 36(2):387-394. PubMed ID: 28832363
[TBL] [Abstract][Full Text] [Related]
17. Intranasal immunization with pneumococcal surface protein A in the presence of nanoparticle forming polysorbitol transporter adjuvant induces protective immunity against the Streptococcus pneumoniae infection.
Kye YC; Park SM; Shim BS; Firdous J; Kim G; Kim HW; Ju YJ; Kim CG; Cho CS; Kim DW; Cho JH; Song MK; Han SH; Yun CH
Acta Biomater; 2019 May; 90():362-372. PubMed ID: 30922953
[TBL] [Abstract][Full Text] [Related]
18. A Novel PspA Protein Vaccine Intranasal Delivered by Bacterium-Like Particles Provides Broad Protection Against Pneumococcal Pneumonia in Mice.
Wang D; Lu J; Yu J; Hou H; Leenhouts K; Van Roosmalen ML; Gu T; Jiang C; Kong W; Wu Y
Immunol Invest; 2018 May; 47(4):403-415. PubMed ID: 29498560
[TBL] [Abstract][Full Text] [Related]
19. Pertussis toxin improves immune responses to a combined pneumococcal antigen and leads to enhanced protection against Streptococcus pneumoniae.
Salcedo-Rivillas C; Debrie AS; Miyaji EN; Ferreira JM; Raw I; Locht C; Ho PL; Mielcarek N; Oliveira ML
Clin Vaccine Immunol; 2014 Jul; 21(7):972-81. PubMed ID: 24807055
[TBL] [Abstract][Full Text] [Related]
20. Pneumococcal Surface Protein A does not affect the immune responses to a combined diphtheria tetanus and pertussis vaccine in mice.
Lima FA; Miyaji EN; Quintilio W; Raw I; Ho PL; Oliveira ML
Vaccine; 2013 May; 31(20):2465-70. PubMed ID: 23541622
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
